Stick To Basics When It Comes To Investment To Reap Higher Profits

Warren Buffett is one of the most intelligent investors around the world and has amassed a fortune in billions through his smart and decisive investment strategies. He recently shared his views on investment and said that people should do the careful analysis before investing because there are many expensive hedge funds out there that short-change the investors. For customers who solely rely on the hedge funds, it is not a productive thing to do as diversification of investment is essential for wealth generation.

Warren Buffet said that he could generate more money by just investing in S&P 500 Passion income fund than by trusting some of the hedge funds out there. It is correct because there are many funds out there that are falling short of their promises and not getting the returns it promised to its investors.

Tim Armour, CEO, and Chairman at Capital Group, also believes that people should see where their money is going before investing. Tim Armour has done graduation in economics from the Middlebury College. He has over 34 years of experience in the finance world, and all his experience comes from Capital Group, where he started in an associate program. Today, Capital Group has over $1.4 Trillion in assets under management and has operations in all the major financial cities in the world, including in Asia, Africa, Europe, America, and Australia.

Tim Armour believes that the key to right investment is having a vision and a goal and feels that to reach the target, careful and strategic planning is needed.


Persons Wishing to Enter the Expressive World of Multi-Media are Encouraged by Leaders Such as Duda Melzer–CEO and President of Grupo RBS:

It goes without saying: when Brazil has its next career day, at one of its many quality institutions–if certain educators were going to choose from the list of CEOs, Presidents and Leaders of Companies and Governmental Entities, offering students with sheer inspiration: one name on the list would doubtless be that of Duda Melzer.

Duda is the nickname tagged to the illustrious CEO and President–Eduardo Sirotsky Melzer of Grupo RBS. The CEO did not allow mere lineage, to the company’s founder, afford him the opportunity of successfully running a high-profile multi-media operation. Duda Melzer made use of his boundless determination, in way of receiving a top-notch education–one of the best educations money can by: ‘The Harvard School of Business’. Duda Melzer attained a Bachelors and Masters Degree in Business Administration from the prestigious United States University.

The company conglomerate which he oversees is Grupo RBS. The company is comprised of radio stations, television stations, news platforms, newspapers, and other media units. It is the second largest employer of journalists, in Brazil, consisting of six-thousand journalists. The overseeing of such a large operation requires much in the way of business acumen and skill: anyone knows it.

Duda, once again, also known as Eduardo, is head of a conglomerate which requires the type of fundamental leadership, requiring skill, and accomplishment in various executive-level roles. The preceding elements are part of the CEO’s background. His academic history, talents and business achievements make, Eduardo, one of Brazil’s top business authorities and leaders. He, undoubtedly, is the type of leader, persons look up to, in the way of executive leadership.


The Many Hats of Clay Siegall

The Many Hats of Clay Siegall

Clay B. Siegall, PhD, wears many hats throughout his career, acting as Co-founder, President, CEO, and Chairman of the Board at Seattle Genetics.


Seattle Genetics is a biotechnology company, founded in 1997, with it’s mind set on developing and commercializing innovative medical solutions using monoclonal antibody-based therapies for cancer treatment.

This technology is designed to utilize the unique targeting capabilities of monoclonal antibodies to send cell-killing agents directly to cancer cells.

Seattle Genetics has established itself as an industry leader in Antibody Drug Conjugates (ADCs), and works diligently to create antibody-based therapies designed to address unmet medical needs.


Dr. Siegall is a scientist by training, and has established Seattle Genetics on a firm foundation of scientific innovations, and a rigorous research ethic.


Clay Siegall began his college career at the University of Maryland, where he earned his Bachelor in Science. He then went on to The George Washington University where he received his PhD.


Prior to co-founding Seattle Genetics, Dr. Siegall worked with Bristol-Meyers Squibb Pharmaceutical Research Institute

Today, in addition to the many hats he wears at Seattle Genetics, Dr. Siegall also serves as Director at Alder Biopharmaceuticals, Inc, in addition to serving as Director at Ultragenyx Pharmaceutical, Inc.

Remaining a very present force in the scientific community, Dr. Siegall has authored as many as sixty-seven scientific papers, and serves on the Editorial Board of no less than three scientific publications, in addition to being a member on the Board of Scientific Counselors for the Cancer Treatment Research Foundation and holder of nine patents.


In 1995, Dr. Siegall was the recipient of the Pierce Award for his efforts in the field of targeted toxins, and in 2002 he became a finalist in the Ernst & Young Pacific Northwest Entrepreneur of the Year award in the category of healthcare.


Dr. Clay Siegall indeed wears many hats, with nearly twenty years of experience in cancer research and therapeutic drug development, he is a seasoned scientist with an obvious passion for his field.